TENNOR THERAPEUTICS REPORTS POSITIVE PHASE IIA POC DATA FOR RIFAQUIZINONE (TNP-2092), THE FIRST NON-SURGICAL THERAPY CANDIDATE FOR PERIPROSTHETIC JOINT INFECTION

Reuters · 3d ago

Please log in to view news